CHANGE-seq-BE was developed to enable scientists to better understand base editors, an important class of CRISPR precise genome editors.

Innovative research into the gene-editing tool targets influenza’s ability to replicate—stopping it in its tracks.

The gene-editing technology CRISPR shows early promise as a therapeutic strategy for the aggressive and difficult-to-treat brain cancer known as primary glioblastoma, according to new findings. The ...

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St.

A UCO team has applied the genome editing technique, which garnered a Nobel Prize in Chemistry in 2020, to unravel the functions of two genes involved in the metabolism of beans and that could not be ...

CRISPR-Cas9 gene editing relies on a guide RNA that binds to a desired DNA sequence and a Cas9 enzyme that cuts both strands of DNA at that site, creating a double-strand break. Scientists edit the ...

Argininosuccinate lyase deficiency (ASLD), also known as argininosuccinic aciduria, is a disease that has been enriched in the Finnish genetic heritage. In this severe metabolic disease, the body does ...

Preserving the distinction between research purposes and clinical applications, the Human Fertilisation and Embryology Authority (HFEA), a U.K. regulatory body, has approved the use of CRISPR gene ...

CRISPR Therapeutics expects regulatory decisions soon for what would be its first commercialized product. An approval would represent a vote of confidence in the technology CRISPR uses throughout its ...

CRISPR Therapeutics (NASDAQ: CRSP) may be a few months away from a transformation. The company itself isn't changing, but its financial picture may be about to do so. That's because by year-end, ...